PARP inhibitor chemical series

PARP inhibitorRefresh recommended

Nicotinamide mimic pharmacophore to olaparib, niraparib, rucaparib and talazoparib.

Mechanism · PARP inhibitor BioMoa · PARP inhibitor BioMoa bridge · shared ID

Last analysis: 7/20/2026, 2:09:34 AM · 2 weeks cadence · refresh on /analyze · refresh recommended

Data sources: Catalog seed · PubChem · ChEMBL · ClinicalTrials.gov · FDA/EMA
Last updated: 7/20/2026, 2:09:34 AM
Similarity method: Morgan fingerprint, radius 2, 2048 bits, Tanimoto
Verified / known compounds: 4
Exploratory nodes: 2
Abstract scaffolds: 1
Relationship types: Derived (curated) · Fingerprint similarity · Drug-class link

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Spider Web · Flow · Structure table · Compare · SMILES map

Name, 2D structure, SMILES, role, parent, core similarity, and traits. Click a row for details.

Compound	Role	SMILES	Parent	Core sim.	Traits
PARP nicotinamide pharmacophoreAbstract pharmacophoreparp-nicotinamide-corePage	Scaffold	`NC(=O)c1cccnc1`	—	—	PARP · core · Shared pharmacophore / core scaffold. Anchor for the PARP inhibitor chemical series lineag…
Niraparib (Zejula)Verified drugniraparibPage	Drug	`C1=CC(=CC=C1C2=CC=CC=C2C(=O)NC3=CC=C(C=C3)…`	PARP nicotinamide pharmacophore	16%i	approved · PARP · Approved therapeutic. Niraparib (Zejula) in this family map. · CHEMBL2103875 · CID 24958200
Olaparib (Lynparza)Verified drugolaparibPage	Drug	`CC1=CC(=CC(=C1)C2=CC(=CC=C2)C(=O)N3CCCC3)C…`	PARP nicotinamide pharmacophore	28%i	approved · PARP · PARP1/2 inhibitor — synthetic lethality in BRCA-mutant tumors. · CHEMBL521686 · CID 23725625
Rucaparib (Rubraca)Verified drugrucaparibPage	Drug	`CCC1=CC(=CC(=C1NC(=O)C2=CC=CC(=C2)F)C)C(=O…`	PARP nicotinamide pharmacophore	13%i	approved · PARP · Approved therapeutic. Rucaparib (Rubraca) in this family map. · CHEMBL2016775 · CID 9931953
Talazoparib (Talzenna)Verified drugtalazoparibPage	Drug	`CN1C2=NC(=NC2=CC=C1C(=O)NC3=CC(=C(C=C3)C(F…`	PARP nicotinamide pharmacophore	10%i	approved · PARP · Approved therapeutic. Talazoparib (Talzenna) in this family map. · CHEMBL3137336 · CID 135565082
PARP fluoro-aryl analogExploratory analog (rule-generated)parp-sar-fluoroPage	Derivative	`CC1=CC(=CC(=C1)C2=CC(=CC=C2)C(=O)N3CCCC3)C…`	PARP SAR indole analog	15%i	SAR · F-scan · SAR exploration node. Derived analog of parent node in PARP inhibitor chemical series.
PARP SAR indole analogExploratory analog (rule-generated)parp-sar-indolePage	Derivative	`CC1=CC(=CC(=C1)C2=CC(=CC=C2)C(=O)N3CCCC3)C…`	Olaparib (Lynparza)	14%i	SAR · SAR exploration node. Derived analog of parent node in PARP inhibitor chemical series.

From the core chemical, derivatives, drugs, and payloads fan out. Dashed orange chords are drug–drug links (spider web).

Loading map…

Clinical · regulatory context

PARP — HRD / BRCA

Olaparib 등. 혈액독성·MDS/AML 경고가 class 이슈입니다.

Approved/clinical labels here come from the catalog clinical overlay. Agency names are shown when curated; live FDA/EMA APIs are not called.

OlaparibApprovedFDA/EMA
BRCA/HRD tumors (ovarian, breast, prostate, pancreas)
ClinicalTrials.gov

Program and pipeline notes live on BioMoa · parp · StructureMoa ↔ BioMoa bridge